Ajanta Pharma Share Price Today | Stock Price & Ajanta Pharma Share Screener
As of November 18, 2026, the live Ajanta Pharma share price (NSE: AJANTPHARM) is ₹3,273.80 on NSE and ₹3,271.90 on BSE, down 1.17% from the previous close, with shares trading between ₹3,268.00 and ₹3,340.00 in today's trading session, and a 52-week range of ₹2,485.70–₹3,718.20. Track AJANTPHARM market cap trends to gauge the company's total market size. Use the Ajanta Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ajanta Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹1,832 and net income of ₹388, with EBITDA of ₹585, an operating margin of 31.0% and a profit margin of 21.2%.
Ajanta Pharma Share Price Chart
Track the current stock price of Ajanta Pharma with an interactive chart. Analyse AJANTPHARM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ajanta Pharma stock quote in one place.
The quote of ₹3,273.80 sits between the 52-week low of ₹2,485.70 and the 52-week high of ₹3,718.20, and the latest session moved -1.17% from the previous close.
Ajanta Pharma Company Profile - Fundamental Screener
Screen Ajanta Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AJANTPHARM shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Mannalal B Agrawal listed as chairperson or CEO, and it trades under ISIN INE031B01049.
Business Overview
Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the...more
Company Details
Classification
Identifiers and Leadership
Ajanta Pharma Balance Sheet Screener
Screen AJANTPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹6,155, up from ₹5,015 in 2025.
Latest statistics put total assets at ₹6,155 and shareholder funds at ₹4,527, with a leverage ratio of 0.04.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 6,155 | 5,015 | 4,638 | 4,679 | 4,056 | 3,779 | 3,319 | 2,696 | 2,449 | 1,848 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 1,867 | 1,762 | 1,479 | 1,496 | 1,512 | 1,541 | 1,472 | 1,178 | 1,053 | 589 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 212 | 229 | 175 | 152 | 144 | 135 | 114 | 73 | 61 | 33 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4,527 | 3,790 | 3,567 | 3,388 | 3,264 | 2,996 | 2,599 | 2,245 | 2,041 | 1,568 |
| Share Capital | 25 | 25 | 25 | 25 | 17 | 17 | 18 | 18 | 18 | 18 |
| Reserves & Surplus | 4,502 | 3,765 | 3,542 | 3,363 | 3,247 | 2,978 | 2,581 | 2,228 | 2,024 | 1,550 |
Ajanta Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Ajanta Pharma income statement and profit fundamentals. Analyze AJANTPHARM quarterly results. Ajanta Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹1,832 and net profit was ₹388, equal to earnings per unit of ₹31.07, at an operating margin of 31%.
In that period expenses were ₹1,247, interest cost ₹2 and tax ₹147. The next period listed, 2026-Jun, shows revenue of ₹1,697 and net profit of ₹334.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 1,832 | 1,697 | 1,483 | 1,400 | 1,413 | 1,329 | 1,189 | 1,177 | 1,206 | 1,171 | 1,090 | 1,119 | 1,050 | 1,053 | 919 |
| Expenses | 1,247 | 1,202 | 1,088 | 993 | 1,026 | 951 | 873 | 825 | 876 | 815 | 776 | 791 | 738 | 750 | 733 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 585 | 495 | 395 | 407 | 387 | 378 | 315 | 351 | 331 | 357 | 314 | 328 | 312 | 303 | 186 |
| Operating Profit % | 31.00% | 26.00% | 23.00% | 28.00% | 24.00% | 27.00% | 25.00% | 28.00% | 26.00% | 29.00% | 26.00% | 28.00% | 28.00% | 27.00% | 17.00% |
| Depreciation | 48 | 45 | 45 | 44 | 43 | 41 | 40 | 36 | 34 | 34 | 34 | 34 | 34 | 33 | 33 |
| Interest | 2 | 3 | 2 | 5 | 3 | 5 | 6 | 8 | 6 | 1 | 2 | 3 | 2 | 1 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 535 | 447 | 347 | 359 | 341 | 331 | 269 | 307 | 290 | 322 | 278 | 291 | 276 | 269 | 152 |
| Tax | 147 | 113 | 80 | 85 | 81 | 76 | 44 | 75 | 74 | 76 | 75 | 81 | 81 | 61 | 30 |
| Net Profit | 388 | 334 | 267 | 274 | 260 | 255 | 225 | 233 | 217 | 246 | 203 | 210 | 195 | 208 | 122 |
| EPS | 31.07 | 26.75 | 21.35 | 21.91 | 20.83 | 20.44 | 18.00 | 18.60 | 17.27 | 19.54 | 16.10 | 16.68 | 15.51 | 16.53 | 9.54 |
Ajanta Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AJANTPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹529, and net cash flow was an outflow of ₹68.
Over the same period, investing activities used ₹429 and financing activities used ₹168.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 529 | 1,157 | 785 | 792 | 562 | 576 | 457 | 375 | 281 | 609 |
| Investing Activities | -429 | -377 | 65 | -560 | -74 | -282 | -224 | -223 | -256 | -383 |
Financing and Net Cash | ||||||||||
| Financing Activities | -168 | -733 | -1,051 | -108 | -460 | -318 | -129 | -148 | 0 | -202 |
| Net Cash Flow | -68 | 47 | -201 | 124 | 28 | -24 | 104 | 4 | 25 | 24 |
Ajanta Pharma Shareholding Pattern Screener
See Ajanta Pharma shareholding pattern with promoter, FII, and DII holdings. Check Ajanta Pharma promoter holding and ownership changes for AJANTPHARM on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 63.47%, foreign institutions 7.63%, domestic institutions 21.94% and the public 6.21%, spread across 61,923 shareholders.
The shareholder count was 61,923 in 2026-Sept, compared with 65,296 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 63.47% | 63.48% | 66.25% | 66.25% | 66.25% | 66.26% | 66.26% | 66.26% |
Institutional Investors | ||||||||
| FII Holding | 7.63% | 7.68% | 8.26% | 7.98% | 8.53% | 8.86% | 8.86% | 9.26% |
| DII Holding | 21.94% | 21.80% | 18.37% | 18.58% | 17.90% | 17.50% | 17.48% | 17.02% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 6.21% | 6.27% | 6.35% | 6.44% | 6.53% | 6.59% | 6.63% | 6.67% |
| Other Holding | 0.75% | 0.76% | 0.77% | 0.76% | 0.79% | 0.79% | 0.76% | 0.79% |
| Shareholder Count | 61,923 | 65,296 | 67,955 | 65,409 | 67,785 | 68,882 | 70,827 | 66,896 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ajanta Pharma. Ajanta Pharma dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹28.00 per unit for 2026-March, a yield of 0.85%, compared with ₹28.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹28.00, ₹28.00 and ₹51.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹28.00 | 0.85% |
| 2025-March | ₹28.00 | 1.00% |
| 2024-March | ₹51.00 | 1.94% |
| 2023-March | ₹7.00 | 0.31% |
| 2022-March | ₹9.50 | 0.79% |
| 2021-March | ₹9.50 | 0.79% |
| 2020-March | ₹13.00 | 1.09% |
| 2019-March | ₹9.00 | 0.99% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹13.00 | 1.40% |
Ajanta Pharma Stock Index Membership - Nifty & Sensex
See which indices include Ajanta Pharma stock. Check AJANTPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 22 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX LMI250.
Complete Index List
Ajanta Pharma Market Events Screener - Corporate Actions
Get Ajanta Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ajanta Pharma stock events that may affect AJANTPHARM share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 30, 2026, with a record date of October 30, 2026.
It is followed by Dividend dated August 5, 2026 and Quarterly Result Announcement dated July 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-30 | 2026-10-30 | Quarterly Result Announcement | NA | 4.87% |
| 2026-08-05 | 2026-08-05 | Dividend | ₹ 32.00 /share | 3.68% |
| 2026-07-30 | 2026-07-30 | Quarterly Result Announcement | NA | -0.57% |
| 2026-07-16 | 2026-07-16 | Annual General Meeting | NA | 10.34% |
| 2026-05-05 | 2026-05-05 | Quarterly Result Announcement | NA | 4.42% |
| 2026-01-30 | 2026-01-30 | Quarterly Result Announcement | NA | -2.63% |
| 2025-11-10 | 2025-11-10 | Dividend | ₹ 28.00 /share | 2.50% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 0.20% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | 3.00% |
| 2025-07-17 | 2025-07-17 | Annual General Meeting | NA | 5.31% |
| 2025-04-30 | 2025-04-30 | Quarterly Result Announcement | NA | 3.24% |
| 2025-01-30 | 2025-01-30 | Quarterly Result Announcement | NA | -8.46% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 28.00 /share | 4.74% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -11.03% |
| 2024-07-18 | 2024-07-18 | Annual General Meeting | NA | -8.03% |
Ajanta Pharma Competitors Screener - Peer Stocks Comparison
Screen AJANTPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,076 | 41.10 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 294,139 | 90.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 178,438 | 84.50 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 119,949 | 98.10 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 118,902 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.70 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,656 | 39.40 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,490 | 48.40 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,223 | 26.40 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,393 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Ajanta Pharma Company Announcements - News & Reports Screener
Screen AJANTPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 13, 2026.
The next most recent announcements are dated November 4, 2026 and November 2, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-13 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-10-30 | Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. | - |
| 2026-10-30 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. | - |
| 2026-10-21 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-10-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-15 | Board Meeting Intimation for Considering And Approving Unaudited Financial Results For Q2 FY 2027 | - |
| 2026-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-06 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-10-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-30 | Submission Of Sustainability Report For FY 2026 | - |
| 2026-09-28 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-18 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-08-31 | Participation In Investor Conference | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-27 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-19 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹3,273.80, within a 52-week range of ₹2,485.70 to ₹3,718.20. The P/E ratio is 32.50 and the P/B ratio is 8.45, with earnings per unit of ₹84.53. Market capitalisation stands at ₹41,993.73 Cr and the dividend yield is 0.97%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.